Literature DB >> 29185157

Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.

Jiro Kikuchi1, Yoshiaki Kuroda1, Daisuke Koyama1, Yusuke Furukawa2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29185157     DOI: 10.1007/s12185-017-2376-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  3 in total

1.  Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.

Authors:  Jiro Kikuchi; Daisuke Koyama; Taeko Wada; Tohru Izumi; Peter O Hofgaard; Bjarne Bogen; Yusuke Furukawa
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

2.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.

Authors:  Takuya Matsunaga; Naofumi Takemoto; Tsutomu Sato; Rishu Takimoto; Ikuta Tanaka; Akihito Fujimi; Takehide Akiyama; Hiroyuki Kuroda; Yutaka Kawano; Masayoshi Kobune; Junji Kato; Yasuo Hirayama; Sumio Sakamaki; Kyuhei Kohda; Kensuke Miyake; Yoshiro Niitsu
Journal:  Nat Med       Date:  2003-08-03       Impact factor: 53.440

3.  Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Authors:  Stefanie Göllner; Thomas Oellerich; Shuchi Agrawal-Singh; Tino Schenk; Hans-Ulrich Klein; Christian Rohde; Caroline Pabst; Tim Sauer; Mads Lerdrup; Sigal Tavor; Friedrich Stölzel; Sylvia Herold; Gerhard Ehninger; Gabriele Köhler; Kuan-Ting Pan; Henning Urlaub; Hubert Serve; Martin Dugas; Karsten Spiekermann; Binje Vick; Irmela Jeremias; Wolfgang E Berdel; Klaus Hansen; Arthur Zelent; Claudia Wickenhauser; Lutz P Müller; Christian Thiede; Carsten Müller-Tidow
Journal:  Nat Med       Date:  2016-12-12       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.